1
Immune claims are being pushed toward proof
The stakes are clinical trust: immune-based medicine must show when a signal is meaningful, when a therapy reaches its target and why some patients respond.
Several immunology topics are less interested in broad claims about boosting immunity than in the details of response, failure and measurement. Laboratory Medicine and Allergy (and clinical immunology) both pick up a skeptical item about paid immune-status testing, which frames the problem clearly: not every measurable immune signal is a useful clinical answer.
Immunology and Biotherapies brings the counterweight: highly specific work on T cells, cancer immunotherapy and in vivo CAR-T therapy. The posts point to questions of delivery, persistence and tumor escape rather than general enthusiasm for immune intervention.
NeuroImmunology widens the field with a glioblastoma CAR-T item focused on the tumor microenvironment. That makes the immune system less a slogan than a setting in which cells, barriers and tissue context determine whether treatment works.
The common thread is a move from immune rhetoric to mechanisms that can be tested. These topics show the same pressure in diagnostics, cancer therapy and neuro-oncology: identify the patient, the pathway and the moment when intervention has a plausible target.
Further reading